EyePoint Pharmaceuticals (NASDAQ:EYPT) has entered into a formal two-year contract with one of the largest integrated delivery systems in the U.S. to offer DEXYCU (dexamethasone intraocular suspension 9%) within its network.
This agreement opens up new distribution channels in California, Washington, Georgia, Colorado and mid-Atlantic states.
Shares are up 12% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.